Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Immunotec Announces New CEO

Published: Monday, May 20, 2013
Last Updated: Monday, May 20, 2013
Bookmark and Share
Immunotec Inc. announced the appointment of Mr. Charles L. Orr as its Chief Executive Officer.

Mr. Orr has served since March 2009 as Executive Director of the Direct Selling Education Foundation, where he held ultimate responsibility for the Foundation's programs and activities. Since 2001, he has provided his proven and successful expertise by active participation as a board member and advisor in a variety of publicly traded and privately held organizations ranging from over a billion dollars in revenue to start-ups. Mr. Orr served as President and Chief Executive Officer of Shaklee Corporation (1993-2000), where he was responsible for the performance of the company's diverse business units. Shaklee, then a $700m revenue company, included the brand names of Harry and David, Jackson and Perkins, and Shaklee. Mr. Orr has been a director of Immunotec since 2006.

Mr. Orr is a seasoned professional with 23 years of experience in the direct selling field. Additionally, his work history includes extensive leadership responsibility in the financial services and computer industries. Mr. Orr was selected as Chief Executive Officer based on a track record leading complex organizations, as well as strong executive and personal qualities. Mr. Orr earned a BA in Psychology from Wesleyan University and an MBA from the University of Connecticut.

In 2005, Mr. Orr received the distinctive Circle of Honor Award from the Direct Selling Education Foundation. In 2007, he was honored by the Direct Selling Association with its prestigious Hall of Fame Award.

Mr. Orr will work out of the Corporation's offices in Vaudreuil, Quebec once all immigration approvals have been obtained.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Immune System 'On Switch' Breakthrough Could Lead to Targeted Drugs
A crucial 'on switch' that boosts the body's defenses against infections has been successfully identified in new scientific research.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Iron Regulators Join War on Pathogens
Iron regulatory proteins (IRPs) play an important role in the body’s immune system.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!